Purpose:
To investigate if metformin use reduces the odds of developing new neovascular AMD (nAMD).
Methods:
This is a case–control study of 86,930 subjects with new diagnoses of nAMD and 86,918 matched control subjects using the Merative Ma…
Purpose:
A previous study from our group demonstrated protective effects of the use of metformin in the odds of developing age-related macular degeneration (AMD). This is a subgroup analysis in a cohort of patients with diabetes to assess the inter…
Purpose:
To investigate the link between lifelong exposure to ultraviolet radiation (UVR) and the development of age-related macular degeneration (AMD).
Methods:
The Alienor study is a prospective population-based cohort involving 963 reside…
No abstract available
Purpose:
To determine the prevalence and rate of persistence over 2 years of various-sized hypertransmission defects (hyperTDs) in eyes with intermediate age-related macular degeneration.
Methods:
Retrospective analysis of optical coherence …
Purpose:
Retinitis pigmentosa GTPase regulator–associated X-linked retinitis pigmentosa (RPGR-associated XLRP) is a rare and severe form of retinitis pigmentosa, resulting in progressive visual impairment; however, disease progression data are limi…
Purpose:
High myopia can occur as a single or syndromic condition. The aim of this study was to evaluate the refractive error and myopic maculopathy in patients with X-linked retinopathies.
Methods:
Whole exome sequencing, Sanger sequencing,…
Purpose:
To determine the utility of ultra-widefield (UWF) imaging in detecting pathologic peripheral retinal tears and holes.
Methods:
This was a retrospective, observational study. One-hundred ninety-eight eyes of 198 patients diagnosed wi…
Purpose:
To investigate the predictors of macular chorioretinal atrophy, consisting of patchy atrophy (PA) at the macula and choroidal neovascularization (CNV)-related macular atrophy (CNV-MA), during treatment with ranibizumab or aflibercept for myopic CNV (mCNV) and its impact on visual outcomes.
Methods:
This retrospective study included 82 eyes with treatment-naïve mCNV who were treated with pro re nata injections of ranibizumab or aflibercept.
Results:
Nine eyes (11.0%) presented with macular PA at baseline (PA group), and 73 eyes (89.0%) did not (non-PA group). VA improved during the first year in the non-PA group; a similar trend was noted in the PA group until 3 months after initial treatment. This improvement was maintained until 24 months (P